↓ Skip to main content

Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study

Overview of attention for article published in Diabetic Medicine, September 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#49 of 3,839)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter
134 X users

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study
Published in
Diabetic Medicine, September 2023
DOI 10.1111/dme.15217
Pubmed ID
Authors

Rossella Cannarella, Rosita A. Condorelli, Claudia Leanza, Vincenzo Garofalo, Antonio Aversa, Giuseppe Papa, Aldo E. Calogero, Sandro La Vignera

X Demographics

X Demographics

The data shown below were collected from the profiles of 134 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Other 1 9%
Student > Bachelor 1 9%
Student > Ph. D. Student 1 9%
Researcher 1 9%
Student > Postgraduate 1 9%
Other 0 0%
Unknown 6 55%
Readers by discipline Count As %
Medicine and Dentistry 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Materials Science 1 9%
Biochemistry, Genetics and Molecular Biology 1 9%
Unknown 6 55%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2023.
All research outputs
#561,300
of 25,904,557 outputs
Outputs from Diabetic Medicine
#49
of 3,839 outputs
Outputs of similar age
#10,229
of 356,729 outputs
Outputs of similar age from Diabetic Medicine
#1
of 51 outputs
Altmetric has tracked 25,904,557 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,839 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,729 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.